413 related articles for article (PubMed ID: 25964636)
21. Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
Guenounou S; Delabesse E; Récher C
Eur J Haematol; 2014 Dec; 93(6):533-6. PubMed ID: 24689895
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
Cortes JE; Kantarjian H; Foran JM; Ghirdaladze D; Zodelava M; Borthakur G; Gammon G; Trone D; Armstrong RC; James J; Levis M
J Clin Oncol; 2013 Oct; 31(29):3681-7. PubMed ID: 24002496
[TBL] [Abstract][Full Text] [Related]
23. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
24. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
[TBL] [Abstract][Full Text] [Related]
25. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
Ravandi F; Alattar ML; Grunwald MR; Rudek MA; Rajkhowa T; Richie MA; Pierce S; Daver N; Garcia-Manero G; Faderl S; Nazha A; Konopleva M; Borthakur G; Burger J; Kadia T; Dellasala S; Andreeff M; Cortes J; Kantarjian H; Levis M
Blood; 2013 Jun; 121(23):4655-62. PubMed ID: 23613521
[TBL] [Abstract][Full Text] [Related]
26. Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia.
Lam SS; Ho ES; He BL; Wong WW; Cher CY; Ng NK; Man CH; Gill H; Cheung AM; Ip HW; So CC; Tamburini J; So CW; Ho DN; Au CH; Chan TL; Ma ES; Liang R; Kwong YL; Leung AY
Sci Transl Med; 2016 Oct; 8(359):359ra129. PubMed ID: 27708062
[TBL] [Abstract][Full Text] [Related]
27. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
Gill H; Man CH; Ip AH; Choi WW; Chow HC; Kwong YL; Leung AY
Haematologica; 2015 Jul; 100(7):e250-3. PubMed ID: 25820334
[No Abstract] [Full Text] [Related]
28. NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A
Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY
Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270
[TBL] [Abstract][Full Text] [Related]
30. [Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
Gu B; Chen GH; Shen HJ; Ma X; Fu CC; Han Y; Tang XW; Miao M; Qiu HY; Sun AN; Wu DP
Zhonghua Nei Ke Za Zhi; 2016 Apr; 55(4):293-7. PubMed ID: 27030618
[TBL] [Abstract][Full Text] [Related]
31. [Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation].
Zhang Y; Xuan L; Fan Z; Huang F; Jiang Q; Xu N; Gao Y; Sun J; Liu Q
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):292-6. PubMed ID: 27093991
[TBL] [Abstract][Full Text] [Related]
32. Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells.
Roolf C; Dybowski N; Sekora A; Mueller S; Knuebel G; Tebbe A; Murua Escobar H; Godl K; Junghanss C; Schaab C
Mol Cell Proteomics; 2017 Jul; 16(7):1365-1376. PubMed ID: 28450419
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience.
Urbino I; Secreto C; Apolito V; Olivi M; Arrigo G; Boscaro E; Catania FM; D'Ardia S; Frairia C; Giai V; Freilone R; Bruno B; Lanzarone G; Giaccone L; Busca A; Dellacasa CM; Ferrero D; Audisio E; Cerrano M
Leuk Res; 2024 Jan; 136():107421. PubMed ID: 38042648
[No Abstract] [Full Text] [Related]
34. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
35. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
Al-Kali A; Cortes J; Faderl S; Jones D; Abril C; Pierce S; Brandt M; Kantarjian H; Ravandi F
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):361-6. PubMed ID: 21816375
[TBL] [Abstract][Full Text] [Related]
36. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
Song G; Valdez BC; Li Y; Liu Y; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1687-95. PubMed ID: 25111583
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With
Burchert A; Bug G; Fritz LV; Finke J; Stelljes M; Röllig C; Wollmer E; Wäsch R; Bornhäuser M; Berg T; Lang F; Ehninger G; Serve H; Zeiser R; Wagner EM; Kröger N; Wolschke C; Schleuning M; Götze KS; Schmid C; Crysandt M; Eßeling E; Wolf D; Wang Y; Böhm A; Thiede C; Haferlach T; Michel C; Bethge W; Wündisch T; Brandts C; Harnisch S; Wittenberg M; Hoeffkes HG; Rospleszcz S; Burchardt A; Neubauer A; Brugger M; Strauch K; Schade-Brittinger C; Metzelder SK
J Clin Oncol; 2020 Sep; 38(26):2993-3002. PubMed ID: 32673171
[TBL] [Abstract][Full Text] [Related]
38. Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation.
Tschan-Plessl A; Halter JP; Heim D; Medinger M; Passweg JR; Gerull S
Ann Hematol; 2015 Nov; 94(11):1899-905. PubMed ID: 26233683
[TBL] [Abstract][Full Text] [Related]
39. Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.
Muppidi MR; Portwood S; Griffiths EA; Thompson JE; Ford LA; Freyer CW; Wetzler M; Wang ES
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S73-9. PubMed ID: 26297284
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases.
Campregher PV; Mattos VRP; Salvino MA; Santos FPS; Hamerschlak N
Einstein (Sao Paulo); 2017; 15(3):355-358. PubMed ID: 28746590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
